In a small 9-person trial, people took Dasatinib and Quercetin for 3 days. Within 11 days, researchers found fewer senescent cells (aging cells that trigger inflammation) in skin and fat tissue, plus lower levels of inflammatory markers in blood like IL-6 and MMP-9. This is the first human study directly showing senolytics can reduce senescent cells, though the sample size is tiny and long-term effects are unknown.

Nine older adults with diabetic kidney disease took oral Dasatinib (100mg) plus Quercetin (1000mg) daily for 3 days. Researchers biopsied skin and fat tissue, plus tested blood, before treatment and 11 days after to measure senescent cell markers and inflammation.

Funded by NIH and private foundations